Aclaris shareholders approve doubling authorized shares to 400M and new equity plan with 25.6M reserve

Aclaris Therapeutics, Inc.

Authorized common shares increased from 200M to 400M via Certificate of Amendment effective June 5, 2025; approved by ~96% of votes.
2025 Equity Incentive Plan approved with 25,556,247 share reserve (9M new shares plus rollover from prior plan).
Directors elected: Neal Walker (71.9M for), Andrew Schiff (71.7M for), William Humphries (56.7M for, 15.99M withheld).
Advisory vote on named executive officer compensation passed 55.5M to 16.98M; PwC ratified as auditor for FY2025.

item 5.02item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.